{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:15:21Z","timestamp":1787872521203,"version":"build-2784847793"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,1,13]],"date-time":"2013-01-13T00:00:00Z","timestamp":1358035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,1,13]],"date-time":"2013-01-13T00:00:00Z","timestamp":1358035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s11940-012-0215-4","type":"journal-article","created":{"date-parts":[[2013,1,12]],"date-time":"2013-01-12T08:49:11Z","timestamp":1357980551000},"page":"185-200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Treatment of Paraneoplastic Cerebellar Degeneration"],"prefix":"10.1007","volume":"15","author":[{"given":"John E.","family":"Greenlee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,13]]},"reference":[{"key":"215_CR1","first-page":"346","volume-title":"Cancer and the nervous system: the neurological manifestations of systemic malignant disease","author":"RA Henson","year":"1982","unstructured":"Henson RA, Urich H. Cortical cerebellar degeneration. In: Henson RA, Urich H, editors. Cancer and the nervous system: the neurological manifestations of systemic malignant disease. Oxford: Blackwell Scientific Publications; 1982. p. 346\u201367."},{"key":"215_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/jnnp.14.2.59","volume":"14","author":"WR Brain","year":"1951","unstructured":"Brain WR, Damiel PM, Greenfield JG. Subacute cortical cerebellar degeneration and its relation to cancer. J Neurol Neurosurg Psychiatry. 1951;14:59\u201375.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"215_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/brain\/57.2.161","volume":"57","author":"JG Greenfield","year":"1934","unstructured":"Greenfield JG. Subacute cerebellar degeneration associated with neoplasms. Brain. 1934;57:161\u201376.","journal-title":"Brain"},{"key":"215_CR4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/brain\/88.3.465","volume":"88","author":"L Brain","year":"1965","unstructured":"Brain L, Wilkinson M. Subacute cerebellar degeneration associated with neoplasms. Brain. 1965;88:465\u201378.","journal-title":"Brain"},{"key":"215_CR5","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1212\/WNL.42.10.1931","volume":"42","author":"K Peterson","year":"1992","unstructured":"Peterson K, Rosenblum MK, Kotanides H, et al. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 1992;42:1931\u20137.","journal-title":"Neurology"},{"key":"215_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/1531-8249(199906)45:6<805::AID-ANA18>3.0.CO;2-G","volume":"45","author":"JE Greenlee","year":"1999","unstructured":"Greenlee JE, Dalmau J, Lyons T, et al. Association of anti-Yo (type I) antibody with paraneoplastic cerebellar degeneration in the setting of transitional cell carcinoma of the bladder: detection of Yo antigen in tumor tissue, and fall in antibody titers following tumor removal. Ann Neurol. 1999;45:805\u20139.","journal-title":"Ann Neurol"},{"key":"215_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1474-4422(08)70060-7","volume":"7","author":"J Dalmau","year":"2008","unstructured":"Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7:327\u201340.","journal-title":"Lancet Neurol"},{"key":"215_CR8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/archneurol.2009.56","volume":"66","author":"HL Pellkofer","year":"2009","unstructured":"Pellkofer HL, Voltz R, Goebels N, et al. Cross-reactive T-cell receptors in tumor and paraneoplastic target tissue. Arch Neurol. 2009;66:655\u20138.","journal-title":"Arch Neurol"},{"key":"215_CR9","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1093\/brain\/awh205","volume":"127","author":"H Pellkofer","year":"2004","unstructured":"Pellkofer H, Schubart AS, Hoftberger R, et al. Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. Brain. 2004;127:1822\u201330.","journal-title":"Brain"},{"key":"215_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/1531-8249(200001)47:1<9::AID-ANA5>3.0.CO;2-I","volume":"47","author":"ML Albert","year":"2000","unstructured":"Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol. 2000;47:9\u201317.","journal-title":"Ann Neurol"},{"key":"215_CR11","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/brain\/aws082","volume":"135","author":"CG Bien","year":"2012","unstructured":"Bien CG, Vincent A, Barnett MH, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain. 2012;135:1622\u201338.","journal-title":"Brain"},{"key":"215_CR12","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1136\/jnnp-2011-301237","volume":"83","author":"L Zuliani","year":"2012","unstructured":"Zuliani L, Graus F, Giometto B, et al. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry. 2012;83:638\u201345.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"215_CR13","doi-asserted-by":"crossref","unstructured":"Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol. 2009;509\u201317.","DOI":"10.1007\/s00415-009-5431-9"},{"key":"215_CR14","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/brain\/120.8.1279","volume":"120","author":"WP Mason","year":"1997","unstructured":"Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain. 1997;120:1279\u2013300.","journal-title":"Brain"},{"key":"215_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJM200001063420104","volume":"342","author":"P Sillevis Smitt","year":"2000","unstructured":"Sillevis Smitt P, Kinoshita A, De Leeuw B, et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med. 2000;342:21\u20137.","journal-title":"N Engl J Med"},{"key":"215_CR16","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1001\/archneurol.2010.51","volume":"67","author":"R Marignier","year":"2010","unstructured":"Marignier R, Chenevier F, Rogemond V, et al. Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease? Arch Neurol. 2010;67:627\u201330.","journal-title":"Arch Neurol"},{"key":"215_CR17","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1001\/archneur.1995.00540290050017","volume":"52","author":"J Honnorat","year":"1995","unstructured":"Honnorat J, Trouillas P, Thivolet C, et al. Autoantibodies to glutamate decarboxylase in a patient with cerebellar cortical atrophy, peripheral neuropathy, and slow eye movements. Arch Neurol. 1995;52:462\u20138.","journal-title":"Arch Neurol"},{"key":"215_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s11940-010-0066-9","volume":"12","author":"JE Greenlee","year":"2010","unstructured":"Greenlee JE. Treatment of paraneoplastic neurologic disorders. Curr Treat Options Neurol. 2010;12:212\u201330.","journal-title":"Curr Treat Options Neurol"},{"key":"215_CR19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/jnnp.68.4.479","volume":"68","author":"F Keime-Guibert","year":"2000","unstructured":"Keime-Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000;68:479\u201382.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"215_CR20","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1468-1331.2006.01266.x","volume":"13","author":"CA Vedeler","year":"2006","unstructured":"Vedeler CA, Antoine JC, Giometto B, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol. 2006;13:682\u201390.","journal-title":"Eur J Neurol"},{"key":"215_CR21","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1136\/jnnp.2003.025171","volume":"75","author":"PM Candler","year":"2004","unstructured":"Candler PM, Hart PE, Barnett M, et al. A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. J Neurol Neurosurg Psychiatry. 2004;75:1411\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"215_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1215\/S1152851703000395","volume":"6","author":"S Vernino","year":"2004","unstructured":"Vernino S, O'Neill BP, Marks RS, et al. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro-Oncol. 2004;6:55\u201362.","journal-title":"Neuro-Oncol"},{"key":"215_CR23","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/brain\/awg133","volume":"126","author":"S Shams'ili","year":"2003","unstructured":"Shams'ili S, Grefkens J, De Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003;126:1409\u201318.","journal-title":"Brain"},{"key":"215_CR24","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1212\/WNL.42.10.1938","volume":"42","author":"J Hammack","year":"1992","unstructured":"Hammack J, Kotanides H, Rosenblum MK, et al. Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin\u2019s disease. Neurology. 1992;42:1938\u201343.","journal-title":"Neurology"},{"key":"215_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jns.2007.07.007","volume":"263","author":"A Poepel","year":"2007","unstructured":"Poepel A, Jarius S, Heukamp LC, et al. Neurological course of long-term surviving patients with SCLC and anti-Hu syndrome. J Neurol Sci. 2007;263:145\u20138.","journal-title":"J Neurol Sci"},{"issue":"Suppl 5","key":"215_CR26","doi-asserted-by":"publisher","first-page":"V33","DOI":"10.1007\/s00415-006-5005-z","volume":"253","author":"R Voltz","year":"2006","unstructured":"Voltz R. Intravenous immunoglobulin therapy in paraneoplastic neurological syndromes. J Neurol. 2006;253 Suppl 5:V33\u20138.","journal-title":"J Neurol"},{"key":"215_CR27","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/archneur.1995.00540320098016","volume":"52","author":"E Stark","year":"1995","unstructured":"Stark E, Wurster U, Patzgold U, et al. Immunological and clinical response to immunosupressive treatment in paraneoplastic cerebellar degeneration. Arch Neurol. 1995;52:814\u20138.","journal-title":"Arch Neurol"},{"key":"215_CR28","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1136\/jnnp.60.4.388","volume":"60","author":"M Uchuya","year":"1996","unstructured":"Uchuya M, Graus F, Vega F, et al. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry. 1996;60:388\u201392.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"215_CR29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/brain\/124.2.437","volume":"124","author":"L Bataller","year":"2001","unstructured":"Bataller L, Graus F, Saiz A, et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain. 2001;124:437\u201343.","journal-title":"Brain"},{"key":"215_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/ana.410290303","volume":"29","author":"FA Luque","year":"1991","unstructured":"Luque FA, Furneaux HM, Ferziger R, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol. 1991;29:241\u201351.","journal-title":"Ann Neurol"},{"key":"215_CR31","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/archneur.1986.00520110055016","volume":"43","author":"KB Digre","year":"1986","unstructured":"Digre KB. Opsoclonus in adults: report of 3 cases and review of the literature. Arch Neurol. 1986;43:1165\u201375.","journal-title":"Arch Neurol"},{"key":"215_CR32","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/ana.10518","volume":"53","author":"SJ Pittock","year":"2003","unstructured":"Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol. 2003;53:580\u20137.","journal-title":"Ann Neurol"},{"key":"215_CR33","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/jnnp.56.1.112","volume":"56","author":"JWB Moll","year":"1994","unstructured":"Moll JWB, Henzen-Logmans SC, Van der Merche FGA, et al. Early diagnosis and intravenous immune globulin therapy in paraneoplastic cerebellar degeneration [letter]. J Neurol Neurosurg Psychiatry. 1994;56:112.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"215_CR34","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/archneurol.2012.595","volume":"69","author":"D Orange","year":"2012","unstructured":"Orange D, Frank M, Tian S, et al. Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens. Arch Neurol. 2012;69:1132\u201340. This recent article details the use of the immunosuppressive agent, tacrolimus, in treatment of paraneoplastic disorders including paraneoplastic cerebellar degeneration. The article outlines a carefully considered approach to treatment. However, the drug had only limited effectiveness in the population studied.","journal-title":"Arch Neurol"},{"key":"215_CR35","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s11060-007-9479-z","volume":"86","author":"M Esposito","year":"2008","unstructured":"Esposito M, Penza P, Orefice G, et al. Successful treatment of paraneoplastic cerebellar degeneration with Rituximab. J Neurooncol. 2008;86:363\u20134.","journal-title":"J Neurooncol"},{"key":"215_CR36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00415-005-0882-0","volume":"253","author":"S Shams'ili","year":"2006","unstructured":"Shams'ili S, de Beukelaar J, Gratama JW, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol. 2006;253:16\u201320.","journal-title":"J Neurol"},{"key":"215_CR37","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/pbc.23314","volume":"58","author":"KK Yeo","year":"2012","unstructured":"Yeo KK, Walter AW, Miller RE, et al. Rituximab as potential therapy for paraneoplastic cerebellar degeneration in pediatric Hodgkin disease. Pediatr Blood Cancer. 2012;58:986\u20137. This recent single case report also suggests a possible role for ritximab in the treatment of paraneoplastic cerebellar degeneration.","journal-title":"Pediatr Blood Cancer"},{"key":"215_CR38","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","volume":"367","author":"EW Gelfand","year":"2012","unstructured":"Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. New Engl J Med. 2012;367:2015-25.","journal-title":"New Engl J Med"},{"key":"215_CR39","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1102::AID-MUS2>3.0.CO;2-C","volume":"20","author":"BM Koffman","year":"1997","unstructured":"Koffman BM, Dalakas MC. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerve. 1997;20:1102\u20137.","journal-title":"Muscle Nerve"},{"key":"215_CR40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","volume":"121","author":"EA Sekul","year":"1994","unstructured":"Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121:259\u201362.","journal-title":"Ann Intern Med"},{"key":"215_CR41","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/00043426-199911000-00012","volume":"21","author":"S Jayabose","year":"1999","unstructured":"Jayabose S, Mahmoud M, Levendoglu-Tugal O, et al. Corticosteroid prophylaxis for neurologic complications of intravenous immunoglobulin G therapy in childhood immune thrombocytopenic purpura. J Pediatr Hematol Oncol. 1999;21:514\u20137.","journal-title":"J Pediatr Hematol Oncol"},{"key":"215_CR42","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1136\/jcp.56.4.308","volume":"56","author":"N Evangelou","year":"2003","unstructured":"Evangelou N, Littlewood T, Anslow P, et al. Transverse sinus thrombosis and IVIg treatment: a case report and discussion of risk-benefit assessment for immunoglobulin treatment. J Clin Pathol. 2003;56:308\u20139.","journal-title":"J Clin Pathol"},{"key":"215_CR43","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1212\/WNL.44.2.223","volume":"44","author":"MC Dalakas","year":"1994","unstructured":"Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994;44:223\u20136.","journal-title":"Neurology"},{"issue":"Suppl 4","key":"215_CR44","doi-asserted-by":"publisher","first-page":"S222","DOI":"10.1007\/s10072-003-0082-6","volume":"24","author":"MM Eibl","year":"2003","unstructured":"Eibl MM. Intravenous immunoglobulins in neurological disorders: safety issues. Neurol Sci. 2003;24 Suppl 4:S222\u20136.","journal-title":"Neurol Sci"},{"key":"215_CR45","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1529-8019.2007.00136.x","volume":"20","author":"J Zwerner","year":"2007","unstructured":"Zwerner J, Fiorentino D. Mycophenolate mofetil. Dermatol Ther. 2007;20:229\u201338.","journal-title":"Dermatol Ther"},{"key":"215_CR46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.12659\/AOT.881859","volume":"16","author":"E Watorek","year":"2011","unstructured":"Watorek E, Boratynska M, Smolska D, et al. Malignancy after renal transplantation in the new era of immunosuppression. Ann Transplant. 2011;16:14\u20138.","journal-title":"Ann Transplant"},{"key":"215_CR47","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1399-0012.2008.00796.x","volume":"22","author":"I Cowlrick","year":"2008","unstructured":"Cowlrick I, Delventhal H, Kaipainen K, et al. Three-year follow-up of malignancies in tacrolimus-treated renal recipients\u2013an analysis of European multicenter studies. Clin Transplant. 2008;22:372\u20137.","journal-title":"Clin Transplant"},{"key":"215_CR48","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.mcna.2012.05.001","volume":"96","author":"D Graves","year":"2012","unstructured":"Graves D, Vernino S. Immunotherapies in neurologic disorders. Med Clin N Am. 2012;96:497\u2013523.","journal-title":"Med Clin N Am"},{"key":"215_CR49","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676\u201388.","journal-title":"N Engl J Med"},{"key":"215_CR50","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","volume":"180","author":"AH Cross","year":"2006","unstructured":"Cross AH, Stark JL, Lauber J, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006;180:63\u201370.","journal-title":"J Neuroimmunol"},{"key":"215_CR51","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1600-0404.2007.00958.x","volume":"117","author":"HF Petereit","year":"2008","unstructured":"Petereit HF, Moeller-Hartmann W, Reske D, et al. Rituximab in a patient with multiple sclerosis\u2013effect on B cells, plasma cells and intrathecal IgG synthesis. Acta Neurol Scand. 2008;117:399\u2013403.","journal-title":"Acta Neurol Scand"},{"key":"215_CR52","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10875-009-9335-3","volume":"30","author":"MR Pranzatelli","year":"2010","unstructured":"Pranzatelli MR, Tate ED, Travelstead AL, et al. Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric Opsoclonus-Myoclonus. J Clin Immunol. 2010;30:106-13.","journal-title":"J Clin Immunol"},{"key":"215_CR53","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","volume":"378","author":"L Kappos","year":"2011","unstructured":"Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicenter trial. Lancet. 2011;378:1779\u201387.","journal-title":"Lancet"},{"key":"215_CR54","doi-asserted-by":"crossref","first-page":"734","DOI":"10.33588\/rn.5412.2012205","volume":"54","author":"O Fernandez","year":"2012","unstructured":"Fernandez O, Alvarez-Cermeno JC, Arroyo-Gonzalez R, et al. Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II). Rev Neurol. 2012;54:734\u201349.","journal-title":"Rev Neurol"},{"key":"215_CR55","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","volume":"65","author":"A Jacob","year":"2008","unstructured":"Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65:1443\u20138.","journal-title":"Arch Neurol"},{"key":"215_CR56","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.semarthrit.2006.01.003","volume":"35","author":"L Min","year":"2006","unstructured":"Min L, Zwerling J, Ocava LC, et al. Reversible posterior leukoencephalopathy in connective tissue diseases. Semin Arthritis Rheum. 2006;35:388\u201395.","journal-title":"Semin Arthritis Rheum"},{"key":"215_CR57","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/MOH.0b013e32834da987","volume":"19","author":"O Wolach","year":"2012","unstructured":"Wolach O, Shpilberg O, Lahav M. Neutropenia after rituximab treatment: new insights on a late complication. Curr Opin Hematol. 2012;19:32\u20138.","journal-title":"Curr Opin Hematol"},{"key":"215_CR58","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113:4834\u201340.","journal-title":"Blood"},{"key":"215_CR59","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/ajh.21484","volume":"84","author":"M Sharma","year":"2009","unstructured":"Sharma M, Moore J, Nguyen V, et al. Fatal CMV pneumonitis in a lymphoma patient treated with rituximab. Am J Hematol. 2009;84:614\u20136.","journal-title":"Am J Hematol"},{"key":"215_CR60","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1399-0012.2009.01044.x","volume":"24","author":"ME Levi","year":"2009","unstructured":"Levi ME, Quan D, Ho JT, et al. Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients. Clin Transplant. 2009;24:223-8.","journal-title":"Clin Transplant"},{"key":"215_CR61","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85\u2013118.","journal-title":"Immunopharmacology"},{"key":"215_CR62","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/mus.21640","volume":"41","author":"MK Hehir","year":"2010","unstructured":"Hehir MK, Burns TM, Alpers J, et al. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve. 2010;41:593\u20138.","journal-title":"Muscle Nerve"},{"key":"215_CR63","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/2047-783X-14-8-364","volume":"14","author":"F Hanisch","year":"2009","unstructured":"Hanisch F, Wendt M, Zierz S. Mycophenolate mofetil as second line immunosuppressant in Myasthenia gravis\u2013a long-term prospective open-label study. Eur J Med Res. 2009;14:364\u20136.","journal-title":"Eur J Med Res"},{"key":"215_CR64","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1001\/archneurol.2012.234","volume":"69","author":"M Mirabelli-Badenier","year":"2012","unstructured":"Mirabelli-Badenier M, Morana G, Pinto F, et al. Anti-glutamic acid decarboxylase limbic encephalitis without epilepsy evolving into dementia with cerebellar ataxia. Arch Neurol. 2012;69:1064\u20136.","journal-title":"Arch Neurol"},{"key":"215_CR65","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1001\/archneurol.2011.106","volume":"68","author":"JR Cornelius","year":"2011","unstructured":"Cornelius JR, Pittock SJ, McKeon A, et al. Sleep manifestations of voltage-gated potassium channel complex autoimmunity. Arch Neurol. 2011;68:733\u20138.","journal-title":"Arch Neurol"},{"key":"215_CR66","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s00415-010-5476-9","volume":"257","author":"S Saidha","year":"2010","unstructured":"Saidha S, Murphy S, Ronayne A, et al. Treatment of anti-glutamic acid decarboxylase antibody-associated limbic encephalitis with mycophenolate mofetil. J Neurol. 2010;257:1035\u20138.","journal-title":"J Neurol"},{"key":"215_CR67","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1136\/jnnp.2009.178293","volume":"81","author":"SH Wong","year":"2010","unstructured":"Wong SH, Saunders MD, Larner AJ, et al. An effective immunotherapy regimen for VGKC antibody-positive limbic encephalitis. J Neurol Neurosurg Psychiatry. 2010;81:1167\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"215_CR68","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s12348-011-0041-y","volume":"2","author":"S Hegde","year":"2012","unstructured":"Hegde S, Annamalai R, Biswas J. Extensive herpes zoster involvement following mycophenolate mofetil therapy for sarcoidosis. J Ophthalmic Inflamm Infect. 2012;2:47\u20138.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"215_CR69","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1016\/j.transproceed.2009.06.195","volume":"41","author":"A Sato","year":"2009","unstructured":"Sato A, Amada N, Kikuchi H, et al. Pneumonia due to varicella-zoster virus reinfection in a renal transplant recipient. Transplant Proc. 2009;41:3959\u201361.","journal-title":"Transplant Proc"},{"key":"215_CR70","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1016\/S0041-1345(03)00684-5","volume":"35","author":"R Lauzurica","year":"2003","unstructured":"Lauzurica R, Bayes B, Frias C, et al. Disseminated varicella infection in adult renal allograft recipients: role of mycophenolate mofetil. Transplant Proc. 2003;35:1758\u20139.","journal-title":"Transplant Proc"},{"key":"215_CR71","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.healun.2005.02.002","volume":"24","author":"HJ Eisen","year":"2005","unstructured":"Eisen HJ, Kobashigawa J, Keogh A, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant. 2005;24:517\u201325.","journal-title":"J Heart Lung Transplant"},{"key":"215_CR72","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1177\/0961203311416693","volume":"21","author":"AM Pavlovic","year":"2012","unstructured":"Pavlovic AM, Bonaci-Nikolic B, Kozic D, et al. Progressive multifocal leukoencephalopathy associated with mycophenolate mofetil treatment in a woman with lupus and CD4+ T-lymphocyte deficiency. Lupus. 2012;21:100\u20132.","journal-title":"Lupus"},{"key":"215_CR73","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1532\/IJH97.04084","volume":"80","author":"H Tamaki","year":"2004","unstructured":"Tamaki H, Kawakami M, Ikegame K, et al. Successful treatment of tacrolimus (FK506)-related leukoencephalopathy with cerebral hemorrhage in a patient who underwent nonmyeloablative stem cell transplantation. Int J Hematol. 2004;80:291\u20134.","journal-title":"Int J Hematol"},{"key":"215_CR74","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1001\/archneur.63.7.930","volume":"63","author":"HC Lehmann","year":"2006","unstructured":"Lehmann HC, Hartung HP, Hetzel GR, et al. Plasma exchange in neuroimmunological disorders: part 1: rationale and treatment of inflammatory central nervous system disorders. Arch Neurol. 2006;63:930\u20135.","journal-title":"Arch Neurol"},{"key":"215_CR75","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1212\/WNL.40.10.1621","volume":"40","author":"F Graus","year":"1990","unstructured":"Graus F, Abos J, Roquer J, et al. Effect of plasmapheresis on serum and CSF autoantibody levels in CNS paraneoplastic syndromes. Neurology. 1990;40:1621\u20133.","journal-title":"Neurology"},{"key":"215_CR76","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1212\/WNL.40.7.1085","volume":"40","author":"HM Furneaux","year":"1990","unstructured":"Furneaux HM, Reich L, Posner JB. Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology. 1990;40:1085\u201391.","journal-title":"Neurology"},{"key":"215_CR77","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1002\/(SICI)1097-0142(19961115)78:10<2153::AID-CNCR16>3.0.CO;2-Y","volume":"78","author":"YB David","year":"1996","unstructured":"David YB, Warner E, Levitan M, et al. Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report. Cancer. 1996;78:2153\u20136.","journal-title":"Cancer"},{"key":"215_CR78","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/0967-5868(95)90052-7","volume":"2","author":"TJ O'Brien","year":"1995","unstructured":"O'Brien TJ, Pasaliaris B, D'Apice A, et al. Anti-Yo positive paraneoplastic cerebellar degeneration: a report of 3 cases and review of the literature. J Clin Neurosci. 1995;2:316\u201320.","journal-title":"J Clin Neurosci"},{"key":"215_CR79","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1046\/j.1525-1438.1995.05050396.x","volume":"5","author":"M McCrystal","year":"1995","unstructured":"McCrystal M, Anderson NE, Jones RW, et al. Paraneoplastic cerebellar degeneration in a patient with chemotherapy-responsive ovarian cancer. Int J Gynecol Cancer. 1995;5:396\u20139.","journal-title":"Int J Gynecol Cancer"},{"key":"215_CR80","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1159\/000204012","volume":"94","author":"C Cehreli","year":"1995","unstructured":"Cehreli C, Payzin B, Undar B, et al. Paraneoplastic cerebellar degeneration in association with Hodgkin\u2019s disease: a report of 2 cases. Acta Haematol. 1995;94:210\u20133.","journal-title":"Acta Haematol"},{"key":"215_CR81","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1212\/WNL.41.10.1682","volume":"41","author":"AM Blumenfeld","year":"1991","unstructured":"Blumenfeld AM, Recht LD, Chad DA, et al. Coexistence of Lambert-Eaton myasthenic syndrome and subacute cerebellar degeneration: differential effects of treatment. Neurology. 1991;41:1682\u20135.","journal-title":"Neurology"},{"key":"215_CR82","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/(SICI)1098-1101(2000)15:1\/2<74::AID-JCA6>3.0.CO;2-O","volume":"15","author":"R Weinstein","year":"2000","unstructured":"Weinstein R. Therapeutic apheresis in neurological disorders. J Clin Apher. 2000;15:74\u2013128.","journal-title":"J Clin Apher"},{"key":"215_CR83","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/jca.20143","volume":"22","author":"D Shemin","year":"2007","unstructured":"Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher. 2007;22:270\u20136.","journal-title":"J Clin Apher"},{"key":"215_CR84","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/0303-8467(89)90010-3","volume":"91","author":"HP Schlake","year":"1989","unstructured":"Schlake HP, Husstedt IW, Grotemeyer KH, et al. Paraneoplastic subacute cerebellar degeneration in Hodgkin\u2019s disease. Report of 3 cases and review of the literature. Clin Neurol Neurosurg. 1989;91:329\u201335.","journal-title":"Clin Neurol Neurosurg"},{"key":"215_CR85","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","volume":"13","author":"SG Banugaria","year":"2012","unstructured":"Banugaria SG, Prater SN, McGann JK, et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med. 2012;13:729-36.","journal-title":"Genet Med"},{"key":"215_CR86","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.4049\/jimmunol.1002539","volume":"186","author":"AM Gomez","year":"2011","unstructured":"Gomez AM, Vrolix K, Martinez-Martinez P, et al. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol. 2011;186:2503\u201313.","journal-title":"J Immunol"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-012-0215-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11940-012-0215-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-012-0215-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-012-0215-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:14:37Z","timestamp":1744172077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11940-012-0215-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,13]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["215"],"URL":"https:\/\/doi.org\/10.1007\/s11940-012-0215-4","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,13]]},"assertion":[{"value":"13 January 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}